Analyst Reco. Prelude Therapeutics Incorporated

Equities

PRLD

US74065P1012

Market Closed - Nasdaq Other stock markets 21:00:00 27/06/2024 BST			5-day change	1st Jan Change
3.69 ^USD	-0.27%		-0.40%	-13.58%

06-20	Barclays Downgrades Prelude Therapeutics to Underweight From Equalweight With $3 Price Target	MT
06-12	Transcript : Prelude Therapeutics Incorporated Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 10:40 AM

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Barclays Downgrades Prelude Therapeutics to Underweight From Equalweight With $3 Price Target	06-20	MT
JMP Securities Starts Prelude Therapeutics With Market Outperform Rating, $7 Price Target	03-13	MT
HC Wainwright Downgrades Prelude Therapeutics to Neutral From Buy, Price Target is $5	02-20	MT
Morgan Stanley Downgrades Prelude Therapeutics to Underweight From Equalweight, Cuts Price Target to $4 From $10	12-19	MT
HC Wainwright Trims Prelude Therapeutics' Price Target to $5 From $6, Keeps Buy Rating	11-07	MT
HC Wainwright Adjusts Price Target on Prelude Therapeutics to $6 From $17, Keeps Buy Rating	19/10/23	MT
Barclays Adjusts Price Target on Prelude Therapeutics to $5 From $7, Maintains Equalweight Rating	04/08/23	MT
HC Wainwright Adjusts Price Target on Prelude Therapeutics to $17 From $15, Maintains Buy Rating	17/03/23	MT
HC Wainwright Adjusts Prelude Therapeutics' Price Target to $15 From $16, Keeps Buy Rating	17/11/22	MT
Morgan Stanley Trims Price Target on Prelude Therapeutics to $10 From $11, Maintains Equalweight Rating	15/11/22	MT
Morgan Stanley Downgrades Prelude Therapeutics to Equalweight From Overweight, Cuts Price Target to $11 From $19	09/09/22	MT
Jefferies Initiates Prelude Therapeutics at Buy With $9 Price Target	29/07/22	MT
HC Wainwright Adjusts Prelude Therapeutics Price Target to $16 From $62, Maintains Buy Rating	12/05/22	MT
Morgan Stanley Adjusts Prelude Therapeutics Price Target to $19 From $20, Maintains Overweight Rating	17/03/22	MT
BofA Securities Downgrades Prelude Therapeutics to Neutral From Buy, Adjusts Price Target to $10 From $50	15/03/22	MT
Barclays Downgrades Prelude Therapeutics to Equalweight From Overweight, Adjusts Price Target to $12 From $20	28/02/22	MT
Barclays Adjusts Prelude Therapeutics' Price Target to $20 From $33, Reiterates Overweight Rating	17/11/21	MT
PRELUDE THERAPEUTICS INCORPORATED : Morgan Stanley Upgrades Prelude Therapeutics to Overweight Rating From Equal-Weight, Adjusts Price Target to $35 From $60	11/10/21	MT
PRELUDE THERAPEUTICS INCORPORATED : Barclays Adjusts Prelude Therapeutics' Price Target to $33 from $80, Keeps Overweight Rating	08/10/21	MT
PRELUDE THERAPEUTICS INCORPORATED : BofA Securities Upgrades Prelude Therapeutics to Buy From Neutral; Price Target is $60	27/07/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Prelude Therapeutics Incorporated

Equities

PRLD

US74065P1012

Analyst Reco.

Filters